The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Improvements in right-sided mCRC responses to amivantamab
Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares updated findings from the open-label, Phase Ib/II OrigAMI-1 study (NCT05379595) of amivantamab, a bispecific antibody targeting EGFR and MET. The trial focused on right-sided metastatic tumors in colorectal cancer, as these patients have previously shown a lack of response to anti-EGFR agents. The results showed long response durations and high disease control rates, suggesting a novel approach for overcoming treatment resistance in right-sided metastatic colorectal cancer. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
